UNSPSC 51162620: Dimethoxanate

This classification denotes an antitussive agent with the molecular formula C19H22N2O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1E3KG5FWDB, chemically known as 10h-phenothiazine-10-carboxylic acid, 2-(2-(dimethylamino)ethoxy)ethyl ester but more generally known as dimethoxanate, which bears US NIH Compound Identifier 10610. European Medicines Agency schedules Dimethoxanate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07175MIG.

UNSPSC 51162620 Dimethoxanate is a Commodity code that state and local governments apply to pharmaceutical products including naloxone, over-the-counter medicines, and generic multi-source pharmaceuticals distributed through health departments, emergency response agencies, and cooperative purchasing vehicles. Recent solicitations show procurement focused on ready-to-use pharmaceutical inventory for community health and emergency preparedness rather than dimethoxanate specifically. Issuing bodies include county health departments and state-administered cooperative purchasing alliances coordinating across multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Seminole County, Florida represent the active buyers in the recent record, with MMCAP drawing participation from state and local facilities across multiple states including Oregon.

Geographic activity centers on Florida and Minnesota, with MMCAP's multi-state cooperative model extending reach across participating jurisdictions. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023 (note: date appears misstated in source). MMCAP issued RFP S1070000015802 in January 2026 establishing multiple contracts for generic pharmaceuticals and OTC products across authorized wholesalers, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. Both procurements require vendors to supply through designated distribution channels, maintain cGMP and FDA compliance, and carry comprehensive insurance. The code shows limited recent activity tied directly to dimethoxanate procurement; the tagged opportunities reflect broader pharmaceutical categories under state and local health purchasing.